Tecentriq-Abraxane Prolongs Survival of Advanced Triple-negative Breast Cancer Patients, Study Shows

Tecentriq-Abraxane Prolongs Survival of Advanced Triple-negative Breast Cancer Patients, Study Shows
Combining Tecentriq (atezolizumab) with the chemotherapy Abraxane (nab-paclitaxel) extends overall survival, and survival without cancer progression, in patients with triple negative breast cancer (TNBC) whose cancer is locally advanced or has spread to distant regions in the body, a Phase 3 clinical trial shows. Combo therapy prolonged patients' overall survival particularly in those with PD-L1 positive tumors, who lived nearly 10 months longer. Also, the treatment was considered well-tolerated, causing no unexpected adverse side effects. The interim results of the study were presented at the European Society for Medical Oncology (ESMO) 2018 Congress held Oct. 19-23 in Munich, Germany. They also were published in the report, “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.